Eton Pharmaceuticals, Inc. (ETON) Stock Price & Analysis
Eton Pharmaceuticals, Inc. (ETON) fell 3.51% to USD 42.59 as of July 25, 2026 at 06:49 UTC, according to Nexqual real-time market data.
ETON last closed at USD 44.14; the session ranged USD 42.39–44.55 on volume of 376,931 shares. Market capitalization is $1.17B, with a 52-week range of USD 13.78–44.91 (NGM). Source: Nexqual, July 25, 2026 at 06:49 UTC.
Key Statistics (as of July 25, 2026 at 06:49 UTC)
| Price | USD 42.59 |
|---|---|
| Change | ▼ 3.51% (down) |
| Previous Close | USD 44.14 |
| Open | USD 44.12 |
| Day Range | USD 42.39 – 44.55 |
| 52-Week Range | USD 13.78 – 44.91 |
| Volume | 376,931 shares |
| Market Cap | $1.17B |
| Exchange | NGM |
Technical Analysis (ETON)
Nexqual's technical model rates ETON "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 06:49 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 68.48 (neutral) |
| vs SMA50 | Above (USD 34.44) |
| MACD | 2.65 (positive) |
Analyst Ratings (ETON)
Wall Street analysts rate ETON "Strong Buy" based on 4 analysts, with a mean price target of USD 49.25 (range USD 40–60), per Nexqual as of July 25, 2026 at 06:49 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 49.25 |
| High Target | USD 60 |
| Low Target | USD 40 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (ETON)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD 0.19 |
| Revenue Estimate | $27.11M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.14 vs est 0.14 ▲ beat |
| 2025-12-31 | USD 0.19 vs est 0.2 ▼ miss |
| 2025-09-30 | USD 0.04 vs est 0.16 ▼ miss |
| 2025-06-30 | USD 0.03 vs est 0.02 ▲ beat |
Source: Nexqual, July 25, 2026 at 06:49 UTC.
Financials & Fundamentals (ETON)
| Total Revenue | $86.93M |
|---|---|
| Revenue Growth (YoY) | +40.40% |
| Gross Margin | +59.72% |
| Operating Margin | +11.39% |
| Profit Margin | -1.70% |
| ROE | -5.36% |
| Debt / Equity | 102.11 |
| Current Ratio | 1.21 |
| Total Cash | $19.66M |
| Total Debt | $31.26M |
| Free Cash Flow | $2.44M |
Source: Nexqual, July 25, 2026 at 06:49 UTC.
Financial Health Score (ETON)
Nexqual rates Eton Pharmaceuticals, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 06:49 UTC.
| Growth | Strong — Revenue +105% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 60%, operating 11% |
| Balance Sheet | Mixed — $20M cash vs $31M debt |
| Cash Flow | Mixed — FCF $2M, slim 3.1% margin |
| Efficiency | Critical — ROE -5%, ROA 4.8% |
Ownership (ETON)
| Insider Ownership | +5.32% |
|---|---|
| Institutional Ownership | +65.69% |
| Shares Outstanding | 27.39M |
| Float | 21.05M |
| Short % of Float | +6.29% |
Source: Nexqual, July 25, 2026 at 06:49 UTC.
Leadership (ETON)
Eton Pharmaceuticals, Inc. is led by Sean E. Brynjelsen (age 53), President, CEO & Director, per Nexqual as of July 25, 2026 at 06:49 UTC.
| President, CEO & Director | Sean E. Brynjelsen (age 53) |
|---|---|
| Chief Financial Officer | Judith M. Matthews (age 55) |
| Executive Vice President of Operations | Danka Radosavljevic |
| Senior Vice President of Sales Operations | Scott Grossenbach |
Major Backers & Investors (ETON)
Notable institutional backers of Eton Pharmaceuticals, Inc. include Opaleye Management Inc., EcoR1 Capital, LLC, Nantahala Capital Management, LLC, according to Nexqual as of July 25, 2026 at 06:49 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Opaleye Management Inc. | 10.44% |
| EcoR1 Capital, LLC | 7.93% |
| Nantahala Capital Management, LLC | 4.29% |
| National Philanthropic Trust | 1.8% |
| Morgan Stanley | 1.74% |
| Westside Investment Management, Inc. | 1.71% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.5% |
| Vanguard Group | 7.64% |
| State Street | 2.5% |
| Geode Capital | 2.11% |
Source: Nexqual, July 25, 2026 at 06:49 UTC.
From Eton Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-03-19)
Key Strengths & Strategy (as disclosed to the SEC)
- For example, if we change the manufacturer of a product or our API, the FDA may require stability or other data from the new manufacturer.
- We also rely on our trade secrets, know-how and continuing technological innovation to develop and maintain our proprietary position.
- If we do not comply with applicable requirements, we may be fined, the government may refuse to approve our marketing applications or allow us to manufacture or market our products, and we may be criminally prosecuted.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| FENC | Fennec Pharmaceuticals Inc. | USD 9.99 | ▼ 3.2% |
| AQST | Aquestive Therapeutics, Inc. | USD 3.68 | ▼ 6.6% |
| VRCA | Verrica Pharmaceuticals Inc. | USD 5.02 | ▼ 11.93% |
| HYPD | Hyperion DeFi, Inc. | USD 2.51 | ▼ 9.06% |
| XERS | Xeris Biopharma Holdings, Inc. | USD 8.32 | ▼ 0.72% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 06:49 UTC. This page is informational and not investment advice.